A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy
With its extensive healthcare network and prestigious research institutions, Massachusetts is a prime destination for a diverse array of clinical trials. Renowned centers such as Massachusetts General Hospital, Brigham and Women's Hospital, the Dana-Farber Cancer Institute, and Moderna are at the forefront of these studies.
These institutions are leading the way in advancing medical research and innovation, contributing significantly to the development of new treatments and therapies for both those living in Massachusetts and the wider population.
Why choose Massachusetts for clinical trials?
Massachusetts stands out as a premier location for clinical trials due to its world-class healthcare institutions and robust research ecosystem. These institutions not only offer access to groundbreaking treatments and therapies but also provide participants with exceptional care and close monitoring from top-tier healthcare professionals.
In addition to high-quality clinical care, participating in trials in Massachusetts allows individuals to contribute to groundbreaking research that can lead to significant medical advancements. The state’s vibrant research environment, supported by major universities and a strong biotech industry, ensures that participants are involved in studies that push the boundaries of current medical knowledge.
Common conditions studied in Massachusetts
Massachusetts’ extensive research infrastructure supports a wide range of studies aimed at advancing treatments and improving patient outcomes across several conditions.
Autoimmune diseases
Clinical trials in Massachusetts focus on several autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis (MS). Researchers here explore innovative treatments and seek to advance our understanding of these complex diseases. Trials often investigate novel biologics and small molecule drugs designed to target specific immune pathways and reduce inflammation more effectively.
Trials may also use biomarkers and imaging technologies to better understand disease mechanisms and patient responses to treatment. The state’s strong research infrastructure, combined with access to a diverse patient population, provides an ideal environment for pioneering studies that drive progress in autoimmune disease management and treatment.
Metabolic disorders
Clinical trials for metabolic disorders in Massachusetts focus on exploring new and innovative treatments for a variety of complex conditions. Current trials investigate novel therapies for disorders such as type 1 and type 2 diabetes, obesity, phenylketonuria (PKU), and rare inherited metabolic diseases like Gaucher disease and Pompe disease.
Research includes testing new drug formulations, advanced insulin delivery systems, and gene therapies aimed at correcting underlying metabolic deficiencies. Trials also explore dietary interventions and enzyme replacement therapies to help manage these conditions and improve patient outcomes. Given the complexity of metabolic disorders and their significant impact on quality of life and overall health, these trials are crucial for developing more effective treatment options.
Infectious diseases
With a high number of infectious diseases reported in Massachusetts every year, clinical trials for these conditions have gained prevalence. Clinical trials for infectious diseases in Massachusetts investigate a range of innovative treatments and preventive measures aimed at combating both emerging and established pathogens.
Current trials include studies on novel vaccines for diseases such as COVID-19, influenza, and tuberculosis, exploring new formulations and delivery methods to enhance efficacy and safety. Research also focuses on developing new antiviral and antimicrobial drugs to tackle resistant strains of bacteria and viruses, including trials for treatments targeting HIV/AIDS and hepatitis C. Additionally, trials are evaluating new therapeutic approaches, such as monoclonal antibodies and immune modulators, to improve outcomes for patients with severe infectious diseases.
Cancer
In Massachusetts, cancer clinical trials cover a diverse array of innovative approaches and methodologies, reflecting the state’s leadership in oncology research. Trials are investigating innovative cancer treatments such as immunotherapy, which harnesses the body's immune system to target cancer cells more effectively. These studies explore new checkpoint inhibitors, CAR-T cell therapies, and combination therapies that aim to enhance immune responses against various cancers, including lung, breast, prostate, and leukemia.
Additionally, research includes targeted therapies that focus on specific genetic mutations within cancer cells, offering more precise treatment options with potentially fewer side effects. Studies are also examining novel drug combinations, advanced radiation techniques, and emerging therapies like gene editing and personalized vaccines.
Interested in learning more about how clinical trials for cancer work? Explore our guide to better understand oncology clinical trials and how they contribute to advancing cancer treatments.
Cardiovascular diseases
Cardiovascular disease trials in Massachusetts are exploring a range of innovative approaches aimed at improving treatment outcomes and patient care. With heart disease being one of the leading causes of death in the state, researchers have placed a strong emphasis on learning more about cardiovascular conditions in order to seek new treatment options and preventative measures.
Research includes studies on advanced medications, groundbreaking technologies, and regenerative medicine techniques, such as stem cell therapies, to repair damaged heart tissue and improve cardiac function.
Mental health disorders
In Massachusetts, clinical trials for mental health conditions are exploring a wide range of innovative treatments and therapies aimed at improving outcomes for individuals with various mental health disorders.
Current research includes trials on novel antidepressants and anxiolytics, investigating new mechanisms of action and targeted treatments for conditions such as depression, anxiety disorders, PTSD, and bipolar disorder. Additionally, studies are examining the potential of psychedelic compounds and ketamine for treatment-resistant depression, as well as exploring advanced psychotherapies and digital mental health tools designed to enhance therapeutic efficacy and accessibility.
Neurological disorders
In Massachusetts, neurological disorder studies are aimed at developing new treatments and advancing our understanding of complex neurological conditions. Current trials focus on a variety of disorders including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS).
Research includes studies on novel drug therapies aimed at modifying disease progression, enhancing cognitive function, and improving motor skills. Trials are also exploring innovative approaches such as gene therapy, stem cell therapy, and advanced neurostimulation techniques to target underlying disease mechanisms and provide new therapeutic options.
Local regulations and guidelines
In Massachusetts, clinical trials are governed by a combination of federal and state regulations that ensure the safety, ethics, and scientific integrity of research. Federally, trials adhere to guidelines set by the U.S. Food and Drug Administration (FDA) and the Office for Human Research Protections (OHRP), which oversee study protocols, informed consent processes, and the protection of human subjects.
At state level, Massachusetts follows these federal guidelines alongside its own regulatory framework through agencies such as the Massachusetts Department of Public Health and the Massachusetts Medical Device Industry Council. Local Institutional Review Boards (IRBs) are responsible for reviewing and approving research proposals to ensure compliance with ethical standards and participant protections.
Additionally, Massachusetts requires adherence to state-specific laws concerning informed consent and data privacy, ensuring all clinical research meets both federal and state requirements for ethical conduct and participant safety.
Benefits of participating in clinical trials
Joining a clinical trial provides numerous advantages for participants, such as gaining access to the latest treatments and therapies that are not yet widely available. Participants benefit from comprehensive care provided by leading healthcare professionals, who offer specialized monitoring and support throughout the study.
Moreover, participating in clinical trials contributes to critical medical research, which can lead to major breakthroughs in treatment. By taking part, individuals not only receive early access to cutting-edge medical interventions but also help advance scientific knowledge, ultimately improving healthcare outcomes for future patients.
How to enroll in a clinical trial in Massachusetts
Enrolling in a clinical trial through our platform is a straightforward and user-friendly process. Here's how to get started:
- Identify your trial: Use our intuitive search bar or filter options to locate clinical trials specific to requirements. This first step simplifies the process of finding relevant research studies tailored to your needs.
- Select your preferred location: To find trials conveniently located near you, simply input your preferred location into the dedicated filter bar on the left-hand side of the page.
- Explore study details: For in-depth information about each study, simply click the “Learn More” button. This will provide you with comprehensive details about the trial, including objectives, procedures, and eligibility criteria.
- Complete the health profile: After clicking on the “Get started” button you will be taken to our efficient 5-step application process to provide important health information. This helps us match you with the clinical trial that best fits your needs.
- Submit the application: After completing the application, send it in. A clinical trial coordinator will review it and contact you regarding the possibility of participation.